title: [DNA index and proliferative activity of blastic cells in childhood ALL].
abstract: DNA Index and the pretreatment proliferative activity of blastic cells were assessed in relation to treatment results in 58 children with acute lymphoblastic leukemia. ALL patients were treated with the use of BFM 79 protocol. After the median follow-up time of 32 months p-EFS and p-DFS were 0,425 and 0,495 respectively. There were 35 (56.45%) diploic, 21 (33.81%) hyper-diploic and 2 (3.22%) hypo-diploic patients. There was no statistical difference in p-EFS and p-DFS between diploic and hyper-diploic patients. Patients in I-st remission were characterized by significantly higher percentage of cells remaining in the S-phase of the cell cycle.
authors.affiliation: I Kliniki Chorób Dzieci Katedry Chorób Dzieci PAM.
authors.forename: J
authors.initials: J
authors.lastname: Peregud-Pogorzelski
authors.forename: J
authors.initials: J
authors.lastname: Fydryk
authors.forename: A
authors.initials: A
authors.lastname: Krygier-Stojałowska
authors.forename: T
authors.initials: T
authors.lastname: Urasiński
authors.forename: E
authors.initials: E
authors.lastname: Kamieńska
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004247:DNA / Q000235:genetics*; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008297:Male; D011003:Ploidies; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D016196:S Phase; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004247:DNA; D011241:Prednisone; D003630:Daunorubicin
vernacular_title: Indeks DNA i aktywność proliferacyjna komórek białaczkowych w OBL u dzieci.